MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT) is a leading, cell-engineering-focused company providing platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. MaxCyte, Inc. (NASDAQ: MXCT) Market Cap: $550.54M; Current Share Price: $5.35 Data by YCharts The Company and its...
Biote Corp. (NASDAQ: BTMD) is a leading solutions provider in preventive health care through the delivery of personalized hormone therapy. The Company has developed a comprehensive platform for Biote-certified practitioners to establish and operate a customized hormone optimization program in their practices. Biote-certified practitioners seek...
Amyris, Inc. (NASDAQ: AMRS) is a synthetic biotechnology company that aims to accelerate the world's transition to sustainable consumption through its Lab-to-Market technology platform and clean beauty consumer brands. The Company Amyris is known explicitly for its Lab-to-Market technology platform. It creates a portfolio connection between its...
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) recently announced that the U.S. Food and Drug Administration has granted approval of its New Drug Application (NDA) for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company's proprietary nasal delivery device. Naloxone hydrochloride nasal spray 4mg is...
Cosmos Health Inc., (NASDAQ: COSM), is an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications and medical devices through an extensive, established EU and UK distribution network. The Company identifies, acquires, develops and...
The Beauty Health Company (NASDAQ: SKIN) is a global category-creating company delivering beauty health experiences that help consumers reinvent their relationship with their skin, bodies, and self-confidence. Their flagship brand, HydraFacial, created the category of hydradermabrasion by using a patented vortex-fusion delivery system to cleanse,...
Avise Analytics, a leading equity research firm specializing in micro-cap and small-cap public companies’ research, has reinitiated coverage on Bioxytran, Inc. (OTCQB: BIXT), a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The in-depth...
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), a commercial-stage biopharmaceutical company, is slated to replace ManTech International Corp. (NASDAQ: MANT) in the S&P SmallCap 600 before the opening of trading on Thursday, September 15. The company develops novel medicines for rare chronic neuromuscular and neurological diseases. Its main...
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announced that its Pharmacokinetics Bridging Study – XRX-OXY-101 – Part 2 showed a significant increase in oral bioavailability of XORTX’s proprietary oxypurinol formulation provided with...
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a biopharmaceutical company developing novel treatments for dermatological diseases, announced the acceptance of the New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) for the treatment of plaque psoriasis in adults and adolescents, filed by Arcutis Canada Inc., a subsidiary of...
